The U.S. Center for Medicare & Medicaid Services encouraged health care providers on its blog last month “to prepare for the end” of its COVID-19 waivers and flexibilities “as soon as possible and to begin moving forward to reestablishing previous
…
Category: Regulatory
Generic drug manufacturer Unichem Pharmaceuticals USA must repay 340B covered entities for overcharges found during a 340B program compliance audit, the U.S. Health Resources and Services Administration (HRSA) said yesterday.
HRSA has been auditing five drug manufacturers per year for
…
Congress and the White House should let financially distressed critical access hospitals keep their 340B drug discounts if they opt under a new law to downgrade into emergency hospitals to remain solvent, rural health advocates told federal health officials in
…
Last September, the U.S. Health Resources and Services Administration (HRSA) published a drug manufacturers’ notice to 340B covered entities that it was limiting distribution of a medicine that alleviates a side effect of HIV/AIDS treatment.
It was the fifth limited
…
Total sales in the 340B drug pricing program reached $43.9 billion in 2021, a 15.6% increase over 2020 sales and more than 3.5 times above total sales in 2015 ($12.1 billion), according to federal data obtained by Drug Channels Institute
…
The U.S. Health Resources and Services Administration (HRSA) is letting eligible healthcare providers in flood-devastated Kentucky enroll in the 340B program immediately instead of making them wait until the next quarterly enrollment period in October.
U.S. Health and Human Services
…
Purdue Pharma’s Avrio Health subsidiary is giving 340B covered entities refunds for overcharges on Betasept antiseptic surgical scrub for purchases spanning 16 years—from Q2 2005 through Q2 2021. That period covers more than half of the 340B program’s existence.
During
…
The U.S. Health Resources and Services Administration overnight unveiled a new Contract Pharmacy Services page on the 340B program website that addresses requirements for covered entities but not for pharmaceutical manufacturers.
The webpage links to HRSA’s 2010 contract pharmacy final
…